GRPH logo

Graphite Bio, Inc. Common Stock


GRPH: Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.


Show GRPH Financials

Consumer Interest
SEC Filings

Recent trades of GRPH by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by GRPH's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of GRPH in WallStreetBets Daily Discussion


Recent insights relating to GRPH

CNBC Recommendations

Recent picks made for GRPH stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in GRPH

Corporate Flights

Flights by private jets registered to GRPH